Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- ASCO 2022: Abstract Recommendations From Dr. Lee Schwartzberg for Breast Cancer
- Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants
- Perioperative cfDNA Concentrations Predict the Risk of Recurrence in Patients With Nonmetastatic Breast Cancer
- Survival Outcomes With De-Escalated Neoadjuvant Pertuzumab Plus Trastuzumab With or Without Weekly Paclitaxel in HER2+/HR− Early Breast Cancer
- Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer
- Overall Survival With Ribociclib Plus Letrozole in Advanced Breast Cancer
- Efficacy of Biosimilar HD201 vs Referent Trastuzumab in ERBB2+ Breast Cancer Treated in the Neoadjuvant Setting
- De-Escalation of Adjuvant Endocrine Therapy in Patients With ER-Low–Positive Breast Cancer
- Pyrotinib Plus Capecitabine for Patients With HER2-Positive Breast Cancer and Brain Metastases